[go: up one dir, main page]

ES2097209T3 - Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno. - Google Patents

Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.

Info

Publication number
ES2097209T3
ES2097209T3 ES91910595T ES91910595T ES2097209T3 ES 2097209 T3 ES2097209 T3 ES 2097209T3 ES 91910595 T ES91910595 T ES 91910595T ES 91910595 T ES91910595 T ES 91910595T ES 2097209 T3 ES2097209 T3 ES 2097209T3
Authority
ES
Spain
Prior art keywords
nalmefene
aid
treatment procedure
alcoholism
alcoholism treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910595T
Other languages
English (en)
Inventor
John D Sinclair
Harry Scheinin
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alko Oy AB
Orion Oyj
Original Assignee
Alko Oy AB
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Oy AB, Orion Yhtyma Oy filed Critical Alko Oy AB
Application granted granted Critical
Publication of ES2097209T3 publication Critical patent/ES2097209T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DEL ALCOHOLISMO. SE SUPRIME LA RESPUESTA A LA INGESTION DEL ALCOHOL DE LOS ALCOHOLICOS HACIENDOLES BEBER BEBIDAS ALCOHOLICAS MIENTRAS QUE EL NALMEFENO, UN ANTAGONISTA DEL OPIO, BLOQUEA EL EFECTO DE REFUERZO POSITIVO DEL ETANOL EN EL CEREBRO.
ES91910595T 1990-06-04 1991-05-10 Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno. Expired - Lifetime ES2097209T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
ES2097209T3 true ES2097209T3 (es) 1997-04-01

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910595T Expired - Lifetime ES2097209T3 (es) 1990-06-04 1991-05-10 Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.

Country Status (19)

Country Link
US (1) US5086058A (es)
EP (1) EP0531415B1 (es)
JP (1) JP3059213B2 (es)
AT (1) ATE145329T1 (es)
AU (1) AU642748B2 (es)
CA (1) CA2084519C (es)
DE (1) DE69123247T2 (es)
DK (1) DK0531415T3 (es)
ES (1) ES2097209T3 (es)
FI (1) FI925513A0 (es)
GR (1) GR3022289T3 (es)
HU (1) HU210637B (es)
IE (1) IE77333B1 (es)
LT (1) LT3893B (es)
LV (1) LV10190B (es)
NZ (1) NZ238391A (es)
RU (1) RU2090190C1 (es)
WO (1) WO1991018605A1 (es)
ZA (1) ZA914185B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
RU2227004C2 (ru) * 2000-06-16 2004-04-20 Писаренко Фаля Юрьевич Способ лечения наркологической зависимости
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP4736323B2 (ja) * 2001-07-13 2011-07-27 アークレイ株式会社 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
RU2200556C1 (ru) * 2001-12-05 2003-03-20 Северцев Владимир Алексеевич Лекарственная форма налтрексона
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
MX2008016372A (es) * 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
RS52041B (sr) * 2008-04-24 2012-04-30 Janssen Pharmaceutica N.V. Prolekovi nalmefena
AU2009239927B2 (en) * 2008-04-24 2014-03-13 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
RU2393864C1 (ru) * 2008-12-29 2010-07-10 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и опиоидной наркомании
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
US20140005216A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
SG10201809280PA (en) * 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
RU2717677C1 (ru) * 2016-04-22 2020-03-25 Тайваньж Фармасьютикалс Со., Лтд. Налмефен, налтрексон или их производные для применения в лечении (не)алкогольного стеатогепатита или неалкогольной жировой болезни печени

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
HU210637B (en) 1995-06-28
NZ238391A (en) 1997-06-24
HUT65523A (en) 1994-06-28
RU2090190C1 (ru) 1997-09-20
IE77333B1 (en) 1997-12-03
CA2084519C (en) 1999-02-09
ATE145329T1 (de) 1996-12-15
CA2084519A1 (en) 1991-12-05
LV10190B (en) 1995-06-20
LTIP1486A (en) 1995-09-25
HU9203835D0 (en) 1993-03-29
AU7974091A (en) 1991-12-31
GR3022289T3 (en) 1997-04-30
DK0531415T3 (da) 1996-12-09
ZA914185B (en) 1992-07-29
AU642748B2 (en) 1993-10-28
WO1991018605A1 (en) 1991-12-12
IE911888A1 (en) 1991-12-04
EP0531415A1 (en) 1993-03-17
EP0531415B1 (en) 1996-11-20
US5086058A (en) 1992-02-04
FI925513L (fi) 1992-12-04
FI925513A7 (fi) 1992-12-04
JP3059213B2 (ja) 2000-07-04
LV10190A (lv) 1994-10-20
JPH06506665A (ja) 1994-07-28
LT3893B (en) 1996-04-25
FI925513A0 (fi) 1992-12-04
DE69123247T2 (de) 1998-01-15
DE69123247D1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
ES2097209T3 (es) Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.
RU92016403A (ru) Способ лечения алкоголизма налмефеном
ES541988A0 (es) Un procedimiento para rebajar el contenido de alcohol de las bebidas alcoholicas.
TR199501122A2 (tr) Etil alkol üretim yöntemi.
DE59004541D1 (de) Verfahren zum Vermindern des Alkoholgehaltes alkoholischer Getränke.
DE3164541D1 (en) Production of ethanol by yeast using xylulose
HU9203838D0 (en) Method for producing isohirudin of improved stability
ES2126889T3 (es) Procedimiento de purificacion de eter 1,1,1,3,3,3-hexafluoroisopropilico de fluorometilo.
DE69719382D1 (de) VERFAHREN ZUR HERSTELLUNG VON rDSPA Alpha1
KR920005710A (ko) 다공질 비트리파이드숫돌의 제조방법
AU2002218231A1 (en) Method for the production of menthalactone
ATE141039T1 (de) Antioxidantienherstellung
JPS5414932A (en) Purification of phenylhydrazine
GB2084607B (en) Method for the production of low alcohol beverages
KR840000885A (ko) 엘더베리(황금포도)음료(음료원액)의 제조방법
DK0431759T3 (da) Fremgangsmåde til fremstilling af et ranitidinharpiksadsorbat
DK591388D0 (da) Mikrobiologisk fremgangsmaade til fremstilling af polycyclisk-ether-forbindelsen uk-61689 og mikroorganismestammer til anvendelse ved fremgangsmaaden
DE69916269D1 (de) Neues verfahren
GEP20063918B (en) Method for the production of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrro-lizin-5-ylacetic acid
KR900009684A (ko) β-시토스테롤의 제조방법
DE68918951D1 (de) Verfahren zur herstellung eines mit einer organischen gruppe substituierten natriumaluminiumhydrids.
KR970006288A (ko) 재결정화 방법을 통한 고순도 바비튜르산의 제조방법
ES2012734A6 (es) Procedimiento para la obtencion de alfa-d-gluco-octono-delta-lactona-eno-diol y su sal calcica.
ITTO920255A0 (it) Procedimento per la produzione di un additivo ricco di etere.
ITTO920253A0 (it) Procedimento per la produzione di un additivo ricco di etere.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531415

Country of ref document: ES